Login or Register to unlock everything MedSchool has to offer!
Full Drug List
 

#

A

B

C

D

E

F

G

H

I

K

N

O

P

Q

R

S

T

U

V

W

Z

 
 

Durvalumab

  •  
    IV infusion
    Durvalumab
    Imfinzi 
    • Mechanism of Action
    • A monoclonal antibody directed against PD-L1, an inhibitory molecule expressed on certain tumour cells.
      PD-L1 and PD-L2 are ligands that bind to PD-1 receptors on activated lymphocytes and inhibit T cell receptor signalling, downregulating immune responses and promoting tolerance.
      Binding of anti-PD-L1 monoclonal antibodies leaves the ligand unable to bind to PD-1, and therefore stimulates an ongoing immune response.
      PD-L2 is not inhibited, allowing PD-1 / PD-L2 mediated inhibitory signals to continue.

Clinical Use

    • Indications
    • Locally advanced non-small cell lung cancer (NSCLC) without progression post chemoradiotherapy
    • Locally advanced or metastatic urothelial carcinoma with progression post platnium-based chemotherapy
    • Adverse Effects
    • Endocrinopathies - thyroiditis, adrenalitis, hypophysitis, diabetes mellitus
    • Pulmonary toxicity - pneumonitis
    • Hepatotoxicity - LFT derangement, hepatitis
    • GI toxicity - colitis
    • Rheumatological - flares of previous disease
    • Skin - rash, pruritis
    • Fatigue
    • Anorexia
    • Headache
    • Dizziness
    • Nausea / vomiting / diarrhoea
    • Thrombocytopaenia

Potential Indications
BETA

Malignant Neoplasms
Feedback